Research Project · Health
Phase II Trial of Naxitamab and Tipifarnib for Relapsed/Refractory Neuroblastoma
Cannonball Kids' Cancercannonballkidscancer.org (opens in a new tab)Catalog updated
No deadline listed
- Amount
- $200,000
- Program type
- Research Project
- Field
- Health
- Eligible career stages
- Not listed
About this program
The Cannonball Kids' Cancer Foundation is offering a $200,000 grant to support a Phase II clinical trial investigating the combination of naxitamab and tipifarnib for treating relapsed/refractory neuroblastoma. This trial, led by Penn State University College of Medicine, aims to enhance the effectiveness of naxitamab by using tipifarnib to counteract tumor-released particles and restore immune function. Eligibility criteria are not specified, but the opportunity is open to researchers focused on advancing neuroblastoma treatment.
In FundFit
Full eligibility
Source announcement
Similar programs
These details are in FundFit.